Thrombosis Clinical Trial
Official title:
Clinical Assessment of Thrombosis in Children After Heart Surgery: The CATCH Study
Thromboembolic complications (TCs) are important causes of morbidity and mortality after
pediatric cardiac surgery, resulting in longer hospital stay, increased risk of early and
late post-surgical complications, early reoperation, neurologic and organ damage, and
potentially death. The true incidence of blood clots in pediatric surgical patients is
unknown.
The overarching objective of this study is to further our understanding of TCs, including
quantification, characterization and risk stratification. This study will ultimately allow
the development of effective tools for prevention and early identification of TCs, rather
than focusing on treatment alone.
There is very limited data on TCs associated with cardiac surgery in pediatric patients. The
actual incidence of TCs in this context is not currently known reflecting a lack of clinical
suspicion, reporting biases, and/or the use of inappropriate diagnostic tests
Pediatric cardiac surgery is associated with disruption of blood flow, platelet dysfunction
and activation, and blood hypercoagulability; all of which are contributing to clot
formation
All congenital heart defects are associated with blood flow disturbance but some are
associated with more extreme disturbances. The investigators hypothesize that not all types
of CHD repairs will be at the same risk of TCs based on the extent of blood flow
disturbances they cause. The investigators hypothesize that line location, difficulties in
line insertion, including multiple insertion attempts and longer duration of indwelling will
be associated with increased risk of TCs.
Pediatric cardiac surgery is associated with inflammation and platelet activation, both of
which are potent contributors to blood hypercoagulability: CPB presents a hemostatic
challenge associated with an abundance of pro-thrombotic risk factors and an opposite
presence of pro-hemorrhagic risk factors. The investigators hypothesize that factors
associated with increased platelet activation and inflammation, and in consequence, greater
laboratory values of markers of platelet activation and inflammation, will be associated
with increased risk of TCs.
Coagulation system activity in children is immature, hyporeactive and exhibits a high degree
of resistance to heparin and anticoagulation. The investigators theorize that lower levels
of coagulation system activity, presence of high-risk genetic polymorphisms, greater CPB
hemodilution, increased heparin requirement and lower blood heparin activity expressed by
anti-factor X activity (anti-Xa) concentration during CPB and greater requirement for
allogeneic blood will be associated for increased risk of TCs.
There is a lack of consensus on clinical and laboratory signs/symptoms of active thrombosis
and on which patients should be routinely screened for TCs. One of the most difficult
aspects in the management of TCs is the fact that many episodes are asymptomatic or have
non-specific symptoms. Creating a risk stratification model including both clinical and
laboratory abnormalities which could be indicative of TCs in the post-operative period in
order to identify patients who should undergo more targeted screening is the third aim of
this study.
Many methods of TC management have limited effectiveness while highly effective methods are
often associated with much risk. The use of thrombolytics in children is rare and only
partially effective in many cases. The margin of safety for treatment is thought to be very
narrow; the reported frequency of major bleeding episodes varies from 5% to 40%.
Outcomes of TCs are suboptimal, early surgical and long-term complications for survivors are
frequent. The creation of risk stratification models for suboptimal surgical outcomes, PTS
syndrome and, lower functional health status after surgery will be the fourth and final aim
of this study.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |